Transthyretin (TTR) amyloid cardiomyopathy is a life-threatening condition in which amyloid fibrils accumulate in the heart, eventually leading to cardiac symptomatology and death. To date, treatment of this condition has been directed a...
Transthyretin amyloid cardiomyopathy (ATTR-CM) ATTR-CM causes deposits of a protein called transthyretin to build up in your heart. It can make the walls of your heart so stiff that your left ventricle can't fill with blood. This can lead to heart failure. ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) ATTR-CM causes deposits of a protein called transthyretin to build up in your heart. It can make the walls of your heart so stiff that your left ventricle can't fill with blood. This can lead to heart failure. ...
For instance, In October 2023, Alnylam Pharmaceuticals, Inc. announced the publication of data from the APOLLO-B Phase 3 study of patisiran in patients with cardiomyopathy of ATTR amyloidosis. When compared to a placebo, the study found that a...
Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of amyloid fibrils in cardiac tissue, causing progressive heart failure (HF) with median survival of 2 to 4 years 1, 2. Two types of amyloid protein cause more than 95% of cardiac amyloidosis: immunoglobulin light...
Generic name: tafamidis meglumine Treatment for: Cardiomyopathy of Transthyretin-Mediated Amyloidosis FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine, Pfizer's Novel Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) ...
Dr Caroline Coats, consultant cardiologist at NHS GreaterGlasgowand Clyde, said: "Transthyretin amyloid cardiomyopathy is a rare, under-diagnosed and potentially life-threatening condition, for which there is a significant unmet medical need.
The US Food and Drug Administration has issued a Complete Response Letter (CRL) for patisiran in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).1 Announced on October 09, 2023, the decision comes less than a month after the FDA’s Cardiovascular and Renal Drugs Advisory Committee...
ATTR-ACT, which showed tafadamis (Pfizer) improved outcomes in patients with certain types of transthyretin amyloid cardiomyopathy, is the trial from ESC Congress “that I think is going to change lives the most,” Gulati, division chief of cardiology for the University of Arizona College ...
(i.e., Kansas City Cardiomyopathy Questionnaire-Overall Summary [KCCQ-OS]). A period of about 18 months was needed before survival curves for all-cause death started to diverge [13]. Patients belonging to the New York Heart Association (NYHA) functional class III displayed no benefit from ...